According to a report from Vaporvoice, United States Senators Joe Manchin, Rand Paul, and Ted Budd have jointly written a letter to the Center for Tobacco Products (CTP) of the Food and Drug Administration (FDA), urging it to reform the pre-market tobacco product application (PMTA) process. Additionally, they have requested the center to provide information regarding policies and actions taken to ensure that its actions are grounded in science and evidence and conducted in an effective manner.
A report highlights that "smoking is a leading cause of preventable diseases and deaths in the United States, with approximately 31 million Americans being smokers," wrote the senators in their letter. "In order to achieve the Food and Drug Administration's goal of reducing harm, an effective authorization process must be in place.
Since 2009, more than 26 million PMTA applications for new products have been submitted in the United States. However, the Center for Tobacco Products (CTP) has only approved less than 50 of these applications. Senators argue that availability of scientifically backed and authorized PMTA or MRTP could potentially improve the health conditions of current smokers using risky tobacco products.
Senators mentioned that in order to achieve the goal of preventing harm to public health, the FDA must have an effective authorization process. Additionally, they also stated that the FDA's authorization speed is far from acknowledging the risk levels of tobacco products.
Senators wrote in a letter, "Previously, CTP attributed its backlog of work to staff shortage, but over the past decade, the number of employees at CTP has grown from 426 in 2013 to over 1,100 now.
According to them, since 2009, the FDA has had the authority to assess and collect user fees from tobacco manufacturers and importers, with these fees reaching $712 million per year since 2019. "With such substantial resources, there should be no reason for the CTP to be incapable of complying with the requirements of the Food, Drug, and Cosmetic Act.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
